Bioasis Technologies Inc (OTCQB:BIOAF) (TSX.V:BTI) CEO Dr. Deborah Rathjen tells Proactive the pre-clinical biopharma group has received positive feedback from the FDA on its pre-investigational new drug (IND) application for its xB3-001 therapy for the treatment of patients with a type of breast cancer and brain metastases. Rathjen says the FDA's favorable feedback included a suggestion the company might consider the next steps of the drug development process towards entering Phase 1 trials.
Full interview: Bioasis Technologies new CEO says favorable response from FDA on its xB3 therapy 'encouraging'
Quick facts: Bioasis Technologies Inc.
Market Cap: $12.31 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE